2016
DOI: 10.1111/all.12932
|View full text |Cite
|
Sign up to set email alerts
|

Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review

Abstract: We found no consistent evidence that SIT is effective for treating AE, but due to the low quality of evidence further research is needed to establish whether SIT has a role in AE treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
42
1
5

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 62 publications
(48 citation statements)
references
References 32 publications
0
42
1
5
Order By: Relevance
“…Since then, allergen immunotherapy has been evaluated in many scientific studies. According to systematic reviews and meta‐analyses, SCIT is helpful in alleviating symptoms and reducing medication in patients with allergic rhinoconjunctivitis and allergic asthma, whereas its benefits for atopic dermatitis (AD) are still unclear . However, some clinical trials and reports of AD patient experience have been highly encouraging .…”
Section: Allergen Immunotherapy (Ait) From Human Beings To Animalsmentioning
confidence: 99%
“…Since then, allergen immunotherapy has been evaluated in many scientific studies. According to systematic reviews and meta‐analyses, SCIT is helpful in alleviating symptoms and reducing medication in patients with allergic rhinoconjunctivitis and allergic asthma, whereas its benefits for atopic dermatitis (AD) are still unclear . However, some clinical trials and reports of AD patient experience have been highly encouraging .…”
Section: Allergen Immunotherapy (Ait) From Human Beings To Animalsmentioning
confidence: 99%
“…SCORAD was reduced from a median of 34.9 [interquartile range 28.75-45.15] at Baseline to 17.2 [12.95-32.3] at the final visit, and IGA improved significantly from 4 [3-4] to 2 [1-3]. We observed a significant improvement in .0] to 12 [8][9][10][11][12][13][14][15][16][17][18], P = .023) and DFI (P = .011), but not CDQLI or POEM. Compared to 6-month period prior to enrolment, there was a significant reduction at six months after the start of the intervention in potent topical corticosteroids (P = .033).…”
mentioning
confidence: 75%
“…Compared to Visit 1, FDQLI at Visit 12 was significantly lower (16.0 [12.25-19.0] to 12 [8][9][10][11][12][13][14][15][16][17][18], P = .02), suggesting improvement, as did DFI (P = .01). Figure S3 shows data on medication use and healthcare utilization.…”
Section: Secondary End-pointsmentioning
confidence: 94%
See 2 more Smart Citations